The efficacy, safety and immunogenicity Nanocovax: results of a randomized, double-blind, placebo-controlled Phase 3 trial.

Thuy Phuong Nguyen; Quyet Do; Lan Trong Phan; Dang Duc Anh; Hiep Khong; Duc Viet Dinh; Luong Van Hoang; Thuong Vu Nguyen; Hung Ngoc Pham; Men Van Chu; Toan Trong Nguyen; Tri Minh Le; Tuyen Thi Ngoc Trang; Thanh Thi Dinh; Thuong Van Vo; Thao Thi Vu; Quynh Bao Phuong Nguyen; Vuong Tan Phan; Luong Viet Nguyen; Giang Truong Nguyen; Phong Minh Tran; Thuan Duc Nghiem; Tien Viet Tran; Tien Gia Nguyen; Tuynh Quang Tran; Linh Tung Nguyen; Anh Tuan Do; Dung Dang Nguyen; Son Anh Ho; Viet Thanh Nguyen; Dung T Pham; Hieu B Tran; Son T Vu; Su Xuan Hoang; Trung Minh Do; Xuan Thanh Nguyen; Giang Quynh Le; Ton Tran; Thang Minh Cao; Huy Manh Dao; Thao Thi Thanh Nguyen; Uyen Y Doan; Vy Thi Tuong Le; Linh Phuong Tran; Ngoc Minh Nguyen; Ngoc Thu Nguyen; Hang Thi Thu Pham; Quan Hoang Nguyen; Quang Duy Pham; Hieu Trung Nguyen; Hang Le Khanh Nguyen; Nguyen Van Trang; Lan Anh Thi Nguyen; Linh Thuy Nguyen; Nhung Thi Hong Trinh; Ly Thi Khanh Le; Van Thi Bao Tran; Mai Thi Ngoc Chu; My Ha Phan; Hoa Thi Hong Nguyen; Vinh The Tran; Mai Thi Nhu Tran; Truc Thi Thanh Nguyen; Phat Tan Ha; Hieu Trong Huynh; Khanh Duy Nguyen; Thuan Trong Ung; Nghia Hoang Trong Duong; Chung Chinh Doan; Si Minh Do.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-22272739

Documentos relacionados

  1. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.
  2. Effect of ArtemiC in patients with COVID-19: A Phase II prospective study.
  3. Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
  4. Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.
  5. Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
  6. Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study.
  7. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
  8. Enhancing clarity of clinical trial safety reports for data monitoring committees.
  9. Safety, tolerability, pharmacokinetics, and immunogenicity of JMB2002-an antibody against COVID-19: a phase 1 clinical trial in healthy Chinese adults.
  10. Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.